As the fourth medicine for Risk-sharing, 'Xtandi soft capsule (enzalutamide)' is likely to be selected

Published: 2014-07-16 10:30:12

Updated: 2014-07-16 10:30:12

As the fourth medicine for Risk-sharing, Astellas Pharmaceutical's prostate cancer treatment 'Xtandi soft capsule (enzalutamide)' is likely to be selected.

On July 10, it was known that Health Insurance Review and Assessment Service evaluated Xtandi suitable for the condition of risk sharing on Pharmaceutical Reimbursement Evaluation Committee. Xtandi will be the fourth medicine for Risk-shar...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.